11 / 33
Keynote 024, Pembrolizumab in PD-L1 positive patients
Reck M, et al. NEJM 2016
HR 0.60
NR both arms
70% vs 54% 1y
|
|
11 / 33
11 / 33
Keynote 024, Pembrolizumab in PD-L1 positive patients
Reck M, et al. NEJM 2016
HR 0.60
NR both arms
70% vs 54% 1y